Clinical characteristics of the patients who had and who did not have MACE
| Event-free group | MACE group | p Value | |
| (n=167) | (n=46) | ||
| Age (years) | 67 (11) | 73 (10) | <0.001 |
| Gender (male) | 128 (76.6%) | 30 (65.2%) | 0.168 |
| Anterior MI | 83 (49.7%) | 28 (60.9%) | 0.240 |
| Smoking | 99 (59.3%) | 26 (56.5%) | 0.867 |
| Obesity | 50 (29.9%) | 9 (19.6%) | 0.228 |
| History of hypertension | 119 (71.3%) | 35 (76.1%) | 0.644 |
| Diabetes mellitus | 58 (34.7%) | 17 (37.0%) | 0.916 |
| History of dyslipidaemia | 95 (56.9%) | 27 (58.7%) | 0.959 |
| PCI | 155 (92.8%) | 20 (43.5%) | <0.001 |
| Peak CPK (IU/l) | 2111 (1309, 3400) | 4199 (1354, 6357) | 0.001 |
| LV parameters | |||
| EDV (ml) | 69.4 (26.1) | 122.0 (52.4) | <0.001 |
| ESV (ml) | 36.7 (20.5) | 79.2 (40.9) | <0.001 |
| LVEF (%) | 49.4 (11.9) | 37.2 (10.4) | <0.001 |
| [123I]MIBG scintigraphy | |||
| TDS | 24.7 (6.2) | 36.7 (7.7) | <0.001 |
| H/M ratio | 209 (29) | 166 (25) | <0.001 |
| WR (%) | 32.6 (9.2) | 50.5 (9.0) | <0.001 |
| Infarcted RDSI | 2.8 (0.7) | 3.4 (0.5) | <0.001 |
| Non-infarcted RDSI | 0.7 (0.3) | 1.4 (0.5) | <0.001 |
| Pharmacotherapy | |||
| ACE inhibitor | 55 (32.9%) | 16 (34.8%) | 0.953 |
| ARB | 81 (48.5%) | 22 (47.8%) | 0.935 |
| β blocker | 123 (73.7%) | 22 (47.8%) | 0.002 |
| MR antagonist | 44 (26.3%) | 18 (39.1%) | 0.132 |
| Nicorandil | 94 (56.3%) | 6 (13.0%) | <0.001 |
| Nitrate | 42 (25.1%) | 16 (34.8%) | 0.266 |
| Calcium channel blocker | 40 (24.0%) | 13 (28.3%) | 0.685 |
Values are mean (SD), median (25%, 75% quartiles), or number (%).
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CPK, creatine kinase; EDV, end-diastolic volume; ESV, end-systolic volume; H/M, heart/mediastinum count; LVEF, left ventricular ejection fraction; MACE, major adverse cardiac events; MI, myocardial infarction; MIBG, m-iodobenzylguanidine; MR, mineralocorticoid receptor; PCI, percutaneous coronary intervention; RDSI, regional defect score index; TDS, total defect score; WR, washout rate.